Drugs / CUR-N399
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05016687 | Jul 2021 → Mar 2022 | chronic obstructive pulmonary disease, enterovirus infectious disease, viral respiratory tract infection | Curovir AB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUR-N399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05016687 ↗ |
| Action | Inhibit | “a PI4KB inhibitor” NCT05016687 ↗ |
| Route | Oral | “CUR-N399 will be administered as oral capsules.” NCT05016687 ↗ |
| Target | PI4KB | “a PI4KB inhibitor” NCT05016687 ↗ |